Company / R&D per Share
AVADEL PHARMACEUTICALS PLC R&D per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.16
FY2024
5-year range
$0.16 / $0.37
FY2020-FY2024
Trend
-3.4%
vs FY2023
Sector context
#195 of 208
Health Care
What the data says
Among 208 Health Care companies, AVADEL PHARMACEUTICALS PLC is in the bottom 6% for r&d per share. R&D per Share has fluctuated over the past 10 years, ranging from $0.16 in FY2024 to $1.05 in FY2018.
Based on SEC 10-K filings.
0.16 in FY2024 with a 5-year CAGR of -28.9%.
Declined from $0.34 to $0.16 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -18.2%
- 5-Year CAGR
- -28.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 208This company $0.16 Sector average $28.82
▼
-99.4% below sector average
Key checks
Key Insights
- In FY2024, r&d per share decreased 3.4% year-over-year.
- Ranks #195 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.16 | -3.4% |
| FY2023 | $0.17 | -52.0% |
| FY2022 | $0.34 | +17.9% |
| FY2021 | $0.29 | -21.5% |
| FY2020 | $0.37 | -57.7% |
| FY2019 | $0.88 | -16.5% |
| FY2018 | $1.05 | +31.7% |
| FY2017 | $0.80 | -4.6% |
| FY2016 | $0.84 | +42.9% |
| FY2015 | $0.59 | +22.9% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026